Videos

In Urology Times’ monthly installment of Around the Practice, experts discuss adverse event management from various treatments for prostate and bladder cancer.

In Urology Times’ monthly installment of Around the Practice, experts discuss adverse event management from various treatments for prostate and bladder cancer.

In Urology Times’ monthly installment of Around the Practice, experts discuss adverse event management from various treatments for prostate and bladder cancer.

Jason Zhu, MD, discusses how next-generation imaging is critical to advancing personalized medicine in prostate cancer.

In this video, Jennifer M. Taylor, MD, MPH, also shares one of her strategies to cope with burnout and provides advice for others struggling with burnout.

Phillip Kuo, MD, PhD, reviews the sensitivity of PSMA (prostate-specific membrane antigen) PET (positron emission tomography) scans compared to conventional imaging.

Andre Abreu, MD, discusses the rationale behind targeting PSMA (prostate-specific membrane antigen) and its impact on the patient journey from diagnosis to biochemical recurrence.

Ranjith Ramasamy, MD, explains how the oral testosterone capsule Jatenzo works and touches on key findings from a recent study of the treatment.

“I think doctors should be aware that if men do complain of erectile dysfunction after [having] COVID-19 that it could be because of underlying endothelial dysfunction and underlying vasculature issues,” Ramasamy says.

Looking back at the November 2020 installment of Urology Times’ Around the Practice, a virtual, monthly live case event focused on genitourinary cancers, Raoul S. Concepcion, MD, FACS, offers an update on clinical implications from two prostate cancer cases.

The history and resultant benefits of PET (positron emission tomography) along with the utilization of PSMA (prostate-specific membrane antigen) PET imaging in treating prostate cancer is discussed.

Andre Abreu, MD, and Phillip Kuo, MD, PhD, define the standard of care and the limitations in prostate cancer imaging.

“We found that there is going to be a significant proportion of growth in the urology work force related to the number of women in urology, which is really exciting,” says Kate H. Kraft, MD.

The PARP inhibitors olaparib and rucaparib are approved by the FDA for prostate cancer and other PARP agents are moving through the pipeline.

Ellimoottil also discusses the status of his own practice with regards to in-person vs telemedicine visits.

“Speak out. speak out. If you're a physician who's going through a hard time, I can promise you you're not alone,” says Raj S. Pruthi, MD, MHA, FACS.

“I really fell in love with [urology] from the get go,” Kraft says.

“In this study, we show that AI can be used to speed up the time-consuming step of outlining the prostate that's required for targeted prostate biopsy,” says Geoffrey Sonn, MD.

The risk assessment tool helps determine whether a prostate biopsy is necessary when PSA screening is ambiguous.

“In my opinion, burnout has nothing to do with weakness or laziness or incompetence,” says Raj S. Pruthi, MD, MHA, FACS.

Dr Raoul Concepcion leads a multidisciplinary expert panel in a discussion about the challenges of long-term follow-up of prostate cancer in patients with negative bone/CT but positive molecular indicators of recurrence. 

An expert panel discusses the challenges of detecting and managing biochemical recurrence in the context of oligometastatic prostate cancer. 

Dr Munir Ghesani reviews and comments on data regarding the sensitivity of imaging modalities in detecting biochemical recurrence in prostate cancer. 

Kretschmer highlights how ongoing research is aiming to optimize use of this noninvasive, urine-based genomic test.

The rationale for utilizing fluoroscopic imaging as well as other evolving technologies that are currently being developed and explored in urology.

Reactions to advances in the quality and safety of newer imaging tests used in prostate cancer.

“Suicide is a disproportionate cause of mortality in physicians,” Pruthi says.

Dr Brad Schwartz comments on his satisfaction with current imaging systems used in urology and the impact of image quality on treatment decisions and clinical outcomes.

Dr Raoul Concepcion leads a panel discussion on a case of a 64-year-old man with multifocal prostate cancer treated with IMRT who refused ADT. 

The ExoDx Prostate test helps physicians determine whether a prostate biopsy is necessary when PSA screening is ambiguous.